<DOC>
	<DOCNO>NCT00336024</DOCNO>
	<brief_summary>This randomized phase III trial study two different combination chemotherapy regimens compare well work give peripheral stem cell transplant treat young patient newly diagnose supratentorial primitive neuroectodermal tumor high-risk medulloblastoma . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together peripheral stem cell transplant may allow chemotherapy give tumor cell kill . It yet know combination chemotherapy regimen effective give peripheral stem cell transplant treat supratentorial primitive neuroectodermal tumor medulloblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Peripheral Stem Cell Transplant Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors High-Risk Medulloblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine treatment pediatric patient newly diagnose supratentorial primitive neuroectodermal CNS tumor high-risk medulloblastoma intensive induction chemotherapy comprise vincristine , etoposide , cyclophosphamide , cisplatin combination high-dose methotrexate leucovorin calcium follow consolidation chemotherapy comprise carboplatin thiotepa peripheral blood stem cell rescue result higher complete response rate patient treat regimen without high-dose methotrexate leucovorin calcium . SECONDARY OBJECTIVES : I . Determine whether biologic characterization tumor refine therapeutic stratification separate atypical teratoid rhabdoid tumor primitive neuroectodermal tumor ( PNETs ) possibly identify marker value stratification within group PNETs . II . Compare event-free survival pattern failure patient treat regimen . III . Compare acute , chronic , late effect regimen , particularly term tolerance consolidation regimen treatment 2 different induction regimen , patient . IV . Compare gastrointestinal nutritional toxicity regimens patient . V. Compare quality life outcomes patient treat regimen . VI . Compare neuropsychological effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord diagnosis* ( M0 medulloblastoma ≥ 1.5 cm² residual tumor v M1 medulloblastoma [ positive lumbar CSF cytology ] v M2 , M3 , M4 medulloblastoma v supratentorial PNET [ M-stage ] v M0 medulloblastoma &lt; 8 month without residual disease &lt; 1.5 cm² radiographic measurable residual tumor v anaplastic M0 medulloblastoma without residual disease &lt; 1.5 cm² radiographic measurable residual v classic M0 ( nondesmoplastic ) medulloblastoma &lt; 1.5 cm² radiographic measurable residual tumor ) . NOTE : *All diagnose child &lt; 36 month unless otherwise note . INDUCTION THERAPY : Patients randomize 1 2 induction treatment arm . ARM I : Patients receive vincristine IV day 1 , 8 , 15 ; etoposide IV 1 hour day 1-3 ; cyclophosphamide IV 1 hour day 1 2 ; cisplatin IV 6 hour day 3 ; filgrastim ( G-CSF ) IV subcutaneously ( SC ) begin day 4 continue blood count recover . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . ARM II : Patients receive vincristine IV day 1 , 8 , 15 ; high-dose methotrexate IV 4 hour day 1 ; leucovorin calcium IV orally every 6 hour begin day 2 continue methotrexate level safe range . Once methotrexate level safe range , patient receive etoposide IV 1 hour approximately day 4 , 5 , 6 , cyclophosphamide IV 1 hour approximately day 4 5 , cisplatin IV 6 hour approximately day 6 . Patients also receive G-CSF IV SC begin 24 hour completion chemotherapy continue blood count recover . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . In arm , patient stable disease partial response induction therapy proceed second-look surgery follow consolidation therapy . Patients complete response induction therapy proceed directly consolidation therapy . CONSOLIDATION THERAPY : Beginning 6 week completion induction therapy , patient receive consolidation therapy comprise carboplatin IV 2 hour thiotepa IV 2 hour day 1 2 G-CSF IV SC begin day 54 continue blood count recover . Patients also receive autologous peripheral blood stem cell ( PBSC ) IV day 4 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Blood tissue sample collect baseline correlative study , include gene expression profiling , biological marker analysis ( i.e. , cMyc , ErbB2/ErbB4 ) , comparative genome analysis , mutation analysis . After completion study therapy , patient follow periodically 4 year annually thereafter .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Diagnosis 1 follow : Highrisk medulloblastoma define follow : Residual disease &gt; 1.5 cm² Lumbar cerebral spinal fluid cytology positive tumor cell analysis fluid collect either definitive surgery ≥ 10 day definitive surgery unless contraindicate M0 disease child &lt; 8 month age diagnosis M2 M3 metastatic disease MRI M4 disease Supratentorial primitive neuroectodermal tumor ( PNET ) ( Mstage ) Anaplastic medulloblastoma regardless Mstage residual tumor M0 classic , nondesmoplastic medulloblastoma ( R1 ) radiographically measurable residual disease &lt; 1.5 cm^2 MRI evidence spinal disease Tumor must negative INI1 gene Has undergone definitive surgery within past 31 day No atypical teratoid rhabdoid tumor Biological specimen must available correlative laboratory study Life expectancy &gt; 8 week Creatinine clearance radioisotope glomerular filtration rate ≥ 60 mL/min Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN Shortening fraction ≥ 27 % echocardiogram Ejection fraction ≥ 47 % radionuclide angiogram No evidence dyspnea rest Pulse oximetry &gt; 94 % room air Absolute neutrophil count &gt; 1,000/mm³ Platelet count &gt; 100,000/mm³ ( transfusion independent ) Hemoglobin &gt; 8 g/dL ( RBC transfusion allow ) Prior corticosteroid allow No prior radiation therapy chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>